MA44489A - Pyrimidines et variants de celles-ci, et leurs utilisations - Google Patents
Pyrimidines et variants de celles-ci, et leurs utilisationsInfo
- Publication number
- MA44489A MA44489A MA044489A MA44489A MA44489A MA 44489 A MA44489 A MA 44489A MA 044489 A MA044489 A MA 044489A MA 44489 A MA44489 A MA 44489A MA 44489 A MA44489 A MA 44489A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrimidins
- variants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44489A true MA44489A (fr) | 2019-01-30 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044489A MA44489A (fr) | 2016-03-25 | 2017-03-20 | Pyrimidines et variants de celles-ci, et leurs utilisations |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (fr) |
| EP (1) | EP3433258B1 (fr) |
| JP (1) | JP6902045B2 (fr) |
| KR (1) | KR102377805B1 (fr) |
| CN (1) | CN108779119B (fr) |
| AU (1) | AU2017237929B2 (fr) |
| CA (1) | CA3018180C (fr) |
| MA (1) | MA44489A (fr) |
| MX (1) | MX384368B (fr) |
| RU (1) | RU2760733C2 (fr) |
| WO (1) | WO2017165255A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017160569A1 (fr) | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| AU2017237929B2 (en) | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| US10633341B2 (en) | 2016-12-19 | 2020-04-28 | Novartis Ag | Picolinic acid derivatives and their use as intermediates |
| CN110087654A (zh) * | 2016-12-20 | 2019-08-02 | 传入制药公司 | P2x3拮抗剂的结晶盐和多晶型物 |
| CN117186068A (zh) * | 2017-11-01 | 2023-12-08 | 北京泰德制药股份有限公司 | P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途 |
| CN107778255B (zh) * | 2017-11-16 | 2019-10-25 | 山东大学 | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
| BR112021021600A2 (pt) * | 2019-04-30 | 2022-01-04 | Beijing Tide Pharmaceutical Co Ltd | Método para tratamento de tosse usando composto de diaminopirimidina |
| EP3960178B1 (fr) * | 2019-04-30 | 2026-03-18 | Beijing Tide Pharmaceutical Co., Ltd. | Procédé de traitement de la douleur associée à l'endométriose à l'aide d'un composé de diaminopyrimidine |
| CA3138234A1 (fr) * | 2019-04-30 | 2020-11-05 | Beijing Tide Pharmaceutical Co., Ltd. | Forme solide de compose de diaminopyrimidine ou d'un hydrate de celui-ci, son procede de preparation et son application |
| EP3981765A4 (fr) | 2019-06-06 | 2023-05-31 | Beijing Tide Pharmaceutical Co., Ltd. | Antagoniste du récepteur p2x3 et/ou p2x2/3, composition pharmaceutique le contenant et son utilisation |
| CN120058573B (zh) * | 2025-04-29 | 2025-12-23 | 潍坊学院 | 一种1-三溴甲基磺酰基萘及其衍生物的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| AU4198400A (en) * | 1999-04-06 | 2000-10-23 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2557372C (fr) * | 2004-03-05 | 2013-01-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines utilisees en tant qu'antagonistes de p2x<sb>3</sb> et p2x<sb>2/3</sb> |
| EP1924564B1 (fr) * | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines en tant que modulateurs de p2x3 et p2x2/3 |
| CN101300012B (zh) * | 2005-09-01 | 2011-09-14 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用 |
| MX2008002731A (es) * | 2005-09-01 | 2008-03-26 | Hoffmann La Roche | Diaminopirimidinas como moduladores de p2x3 y p3x2/3. |
| ES2562056T3 (es) * | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| AU2007304280B2 (en) * | 2006-10-04 | 2013-01-31 | F. Hoffmann-La Roche Ag | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| WO2008104472A1 (fr) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci |
| WO2008104474A1 (fr) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| WO2009057827A1 (fr) * | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Dérivés de pyridazinone et leur utilisation comme inhibiteurs du récepteur p2x7 |
| GB2471713A (en) | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| AU2014308606B2 (en) * | 2013-08-23 | 2017-08-03 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| US10195198B2 (en) * | 2014-07-03 | 2019-02-05 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| WO2017160569A1 (fr) * | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| AU2017237929B2 (en) * | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
-
2017
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 CA CA3018180A patent/CA3018180C/fr active Active
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/ko active Active
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
- 2017-03-20 MA MA044489A patent/MA44489A/fr unknown
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/ja active Active
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/ru active
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/fr not_active Ceased
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/fr active Active
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/zh active Active
- 2017-03-20 MX MX2018011622A patent/MX384368B/es unknown
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019510025A (ja) | 2019-04-11 |
| MX384368B (es) | 2025-03-14 |
| US20190055202A1 (en) | 2019-02-21 |
| US20200239421A1 (en) | 2020-07-30 |
| WO2017165255A1 (fr) | 2017-09-28 |
| JP6902045B2 (ja) | 2021-07-14 |
| BR112018069105A2 (pt) | 2019-01-29 |
| US11230532B2 (en) | 2022-01-25 |
| CA3018180C (fr) | 2024-02-20 |
| CN108779119A (zh) | 2018-11-09 |
| RU2760733C2 (ru) | 2021-11-30 |
| CN108779119B (zh) | 2022-02-08 |
| EP3433258B1 (fr) | 2023-07-19 |
| KR20180128015A (ko) | 2018-11-30 |
| RU2018137032A (ru) | 2020-04-27 |
| US10662162B2 (en) | 2020-05-26 |
| EP3433258A4 (fr) | 2019-10-30 |
| AU2017237929B2 (en) | 2021-04-15 |
| MX2018011622A (es) | 2019-03-28 |
| CA3018180A1 (fr) | 2017-09-28 |
| EP3433258A1 (fr) | 2019-01-30 |
| RU2018137032A3 (fr) | 2020-05-22 |
| AU2017237929A1 (en) | 2018-09-13 |
| KR102377805B1 (ko) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3496757A4 (fr) | Antifolates de polyglutamates et leurs utilisations. | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations | |
| EP3490565A4 (fr) | Modulateurs de récepteurs de chimiokine et leurs utilisations | |
| EP3334706A4 (fr) | Pillararènes et utilisations de ceux-ci | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3328199A4 (fr) | Compositions antimicrobiennes et leurs utilisations | |
| EP3344624A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3325488A4 (fr) | Macrocycles diaryles chiraux et leurs utilisations | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| EP3313530A4 (fr) | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3624797A4 (fr) | Inhibiteurs de kinase et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3347020A4 (fr) | Acétamide thiénotriazoldiazépines et leurs utilisations | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations | |
| EP3370771A4 (fr) | Conjugués anti-cd3-folate et leurs utilisations | |
| EP3664799A4 (fr) | Antibiotiques linconsamides et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
| EP3377897A4 (fr) | Biocapteurs de lactate et leurs utilisations |